Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E. Krop, Howard Burris, Angel Guerrero-Zotano, Carolyn D. Britten, Carlos Becerra, Jan Schellens, Donald A. Richards, Martin Schuler, Maysa Abu-Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, Jose Baselga